Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Get Free Report) major shareholder Paul B. Manning bought 100,000 shares of the company’s stock in a transaction that occurred on Friday, November 17th. The shares were acquired at an average price of $1.63 per share, for a total transaction of $163,000.00. Following the completion of the purchase, the insider now owns 16,566,667 shares in the company, valued at $27,003,667.21. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.
Taysha Gene Therapies Trading Up 1.2 %
Shares of NASDAQ:TSHA opened at $1.72 on Monday. Taysha Gene Therapies, Inc. has a 12-month low of $0.50 and a 12-month high of $3.89. The business has a 50 day moving average of $2.49 and a two-hundred day moving average of $1.62. The company has a market capitalization of $321.57 million, a PE ratio of -0.66 and a beta of 0.13.
Hedge Funds Weigh In On Taysha Gene Therapies
Several large investors have recently made changes to their positions in the company. Swiss National Bank increased its holdings in Taysha Gene Therapies by 9.3% in the first quarter. Swiss National Bank now owns 41,000 shares of the company’s stock valued at $267,000 after buying an additional 3,500 shares in the last quarter. JPMorgan Chase & Co. increased its stake in shares of Taysha Gene Therapies by 85.1% in the 1st quarter. JPMorgan Chase & Co. now owns 439,804 shares of the company’s stock valued at $2,868,000 after purchasing an additional 202,245 shares in the last quarter. Vanguard Group Inc. raised its holdings in Taysha Gene Therapies by 14.5% in the 1st quarter. Vanguard Group Inc. now owns 1,012,164 shares of the company’s stock worth $6,599,000 after purchasing an additional 128,517 shares during the period. Renaissance Technologies LLC purchased a new position in Taysha Gene Therapies during the first quarter worth approximately $1,633,000. Finally, UBS Group AG boosted its position in Taysha Gene Therapies by 33.2% during the first quarter. UBS Group AG now owns 67,980 shares of the company’s stock worth $443,000 after purchasing an additional 16,944 shares in the last quarter. 25.91% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
About Taysha Gene Therapies
Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis.
- Five stocks we like better than Taysha Gene Therapies
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- 2 stocks that under-promised and over-delivered on their earnings
- How to Use the MarketBeat Stock Split Calculator
- 2 overlooked stocks that crushed earnings but traded lower
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- 3 stocks that crushed earnings estimates and still tanked
Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.